A Boston biotech company called FNDA has collaborated with research organizations to utilize artificial intelligence, AI, to aid drug development and disease diagnosis, reports FierceBiotech. They are currently looking for partners to join the Genome Collaborative, a group of organizations working towards the same mission. They hope with the technology they will be able to help millions of patients globally who are undiagnosed.
FDNA shares that the AI they’re constructing will be able to analyze data from images, video and voice recordings, as well as clinical notes. They will be able to use that data to diagnose patients and hopefully lead them in the right direction for medical treatment. The FDNA believes that having this technology will not only benefit the patient, but also the healthcare providers when analyzing the facts of a patient.
FDNA is a very successful company, but is known for their Face2Gene technology. They developed an app that attempts to diagnose a rare disease patient based off of physical features. Clinicians can simply take a photo of the patient with a smartphone and the image will be analyzed in their database to see what possible diseases it matches with. This type of technology will be a vital part in their new project.
Currently, FDNA’s offerings grabbed the attention of Greenwood Genetic Center from South Carolina, Switzerland’s Lausanne University Hospital, as well as Seattle Children’s Hospital. They will conduct research projects with FDNA’s technology. Additionally, Bridge the Gap and All Things Kabuki, both groups for patient advocacy, are joining the team.